Evidence map›Paper›PMID 21282615›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2011

Crystal structure of the synergistic antibiotic pair, lankamycin and lankacidin, in complex with the large ribosomal subunit.

Matthew J Belousoff, Tal Shapira, Anat Bashan, Ella Zimmerman, Haim Rozenberg, Kenji Arakawa, Haruyasu Kinashi, Ada Yonath

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A Structurally CharacterizedMicrobiology spectrum · 2022
    Article
  9. Review
  10. Review ofInfection and drug resistance · 2022
    Review
  11. Article
  12. New restraints and validation approaches for nucleic acid structures in PDB-REDO.Acta crystallographica. Section D, Structural biology · 2021
    Article
  13. Review
  14. Article
  15. Article
  16. Modular Approaches to Lankacidin Antibiotics.Journal of the American Chemical Society · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Matthew J BelousoffDepartment of Structural Biology, Weizmann Institute of Science, Rehovot, 76100, Israel.
Tal Shapira
Anat Bashan
Ella Zimmerman
Haim Rozenberg
Kenji Arakawa
Haruyasu Kinashi
Ada Yonath
Weizmann Institute of Science · ILHiroshima University · JP

Funding

Novel Therapeutics for Bacillus anthracisU19AI056575 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI JOHNSON, MICHAEL E. · 2003 to 2007
$15.5M
CRYSTALLOGRAPHIC STUDIES ON RIBOSOMAL PARTICLESR01GM034360 · NIGMS · WEIZMANN INSTITUTE OF SCIENCE · PI YONATH, ADA E · 1985 to 2010
$2.2M
NIAID NIH HHS U19 AI056575NIAID NIH HHS U19 AI56575NIGMS NIH HHS GM34360NIGMS NIH HHS R01 GM034360
6 · The paper itself

Abstract

The structures of the large ribosomal subunit of Deinococcus radiodurans (D50S) in complex with the antibiotic lankamycin (3.2 Å) and a double antibiotic complex of lankamycin and lankacidin C (3.45 Å) have been determined, in continuation of previous crystallographic studies on lankacidin-D50S complex. These two drugs have been previously reported to inhibit ribosomal function with mild synergistic effect. Lankamycin, a member of the macrolide family, binds in a similar manner to erythromycin. However, when in complex with lankacidin, lankamycin is located so that it can form interactions with lankacidin in the adjacent ribosomal binding site. When compared to the well-documented synergistic antibiotics, Streptogramins A and B, the pair of lankacidin and lankamycin bind in similar sites, the peptidyl transferase center and nascent peptide exit tunnel, respectively. Herein, we discuss the structural basis for antibiotic synergism and highlight the key factors involved in ribosomal inhibition.

Indexed as

Models, MolecularAnti-Bacterial AgentsBinding SitesCrystallographyDNA FootprintingDrug SynergismErythromycinInhibitory Concentration 50MacrolidesMolecular StructureRibosome Subunits, LargeRNA, Ribosomal, 23SX-Ray DiffractionAnti-Bacterial AgentsErythromycinkujimycin BlankacidinsMacrolidesRNA, Ribosomal, 23S

Identifiers

PMID21282615
PMCPMC3041097
OpenAlexW2113389111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.